Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis
AUPH Stock | USD 8.85 0.25 2.75% |
Under 55% of Aurinia Pharmaceuticals' investor base is interested to short. The analysis of the overall investor sentiment regarding Aurinia Pharmaceuticals suggests that many traders are impartial. Aurinia Pharmaceuticals' investing sentiment shows overall attitude of investors towards Aurinia Pharmaceuticals.
Aurinia |
ROCKVILLE, Md. EDMONTON, Alberta, November 18, 2024--Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis
Read at finance.yahoo.com
Aurinia Pharmaceuticals Current Investor Sentiment
Panic Vs Confidence
45
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Aurinia Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Aurinia Pharmaceuticals.
News SentimentBullish | Hype SentimentBearish | Insider SentimentDisposing |
Aurinia Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Aurinia Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Aurinia Pharmaceuticals Historical Investor Sentiment
Investor biases related to Aurinia Pharmaceuticals' public news can be used to forecast risks associated with an investment in Aurinia. The trend in average sentiment can be used to explain how an investor holding Aurinia can time the market purely based on public headlines and social activities around Aurinia Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Aurinia Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Aurinia Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Aurinia Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Aurinia Pharmaceuticals.
Aurinia Pharmaceuticals Fundamental Analysis
We analyze Aurinia Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aurinia Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aurinia Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Number Of Shares Shorted
Number Of Shares Shorted Comparative Analysis
Aurinia Pharmaceuticals is currently under evaluation in number of shares shorted category among its peers. Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Aurinia Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Aurinia Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Aurinia Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Aurinia Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Aurinia Pharmaceuticals Related Equities
PTCT | PTC Therapeutics | 18.66 | ||||
AXSM | Axsome Therapeutics | 0.88 | ||||
TGTX | TG Therapeutics | 0.83 | ||||
AKRO | Akero Therapeutics | 0.28 | ||||
TERN | Terns Pharmaceuticals | 1.44 | ||||
EXEL | Exelixis | 2.39 | ||||
VKTX | Viking Therapeutics | 2.70 | ||||
MDGL | Madrigal Pharmaceuticals | 2.94 | ||||
SRPT | Sarepta Therapeutics | 4.04 | ||||
MCRB | Seres Therapeutics | 5.10 | ||||
BTAI | BioXcel Therapeutics | 5.16 | ||||
HEPA | Hepion Pharmaceuticals | 5.97 |
Complementary Tools for Aurinia Stock analysis
When running Aurinia Pharmaceuticals' price analysis, check to measure Aurinia Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aurinia Pharmaceuticals is operating at the current time. Most of Aurinia Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aurinia Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aurinia Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aurinia Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |